ADVFN - Advanced Financial Network.
HOME» NYSE » N » NVS Stock Price » NVS Stock News

Novartis Share News

 Novartis Ag Basel Stock Price
NVS Stock Price
 Novartis Ag Basel Stock Chart
NVS Stock Chart
 Novartis Ag Basel Stock News
NVS Stock News
 Novartis Ag Basel Company Information
NVS Company Information
 Novartis Ag Basel Stock Trades
NVS Stock Trades

FDA Approves Novartis's Afinitor For Kidney Tumors

By Jennifer Corbett Dooren Of DOW JONES NEWSWIRES WASHINGTON -(Dow Jones)- The U.S. Food and Drug Administration Thursday granted wider approval to Novartis AG's (NVS, NOVN.VX) Afinitor to treat non-cancerous kidney tumors that don't require immediate surgery. Afinitor was first approved in the U.S. in 2009 to treat kidney cancer after treatment with other drugs fail. Afinitor was approved Thursday to treat kidney tumors that are caused by a rare genetic disese called tuberous sclerosis complex, or TSC. According to FDA, the disease causes the growth of various non-cancerous tumors in the brain, kidney and other vital organs. It affects about 40,000 patients in the U.S., the majority of which develop kidney problems. TSC generally causes multiple tumors in both kidneys, which eventually cause kidney failure and bleeding. Afinitor, a pill taken once daily, blocks the uncontrolled activity of a protein called mTOR, which plays a role in the development and growth of certain tumors. Afinitor is also approved to treat certain kinds of brain and pancreatic tumors. The FDA said the approval of Afinitor for use in treating kidney tumors from TSC was based on a study involving 118 patients. About two-thirds of the patients received Afinitor and one-third were received a placebo, or fake pill. Patients receiving the placebo later had the option to receive Afinitor if their kidney tumors grew. FDA said the study showed about 42% of patients treated with Afinitor experienced "substantial" shrinkage of their tumors which lasted more than five months on average. None of the patients on the placebo had tumor shrinkage. Novartis is being required to keep following patients in the study for at least four years. FDA said the most common side effects with Afinitor were sore mouth, nausea or vomiting, skin problems, cough, headache, diarrhea, abdominal pain, joint pains, swelling of legs or arms, and upper respiratory infections. -By Jennifer Corbett Dooren; Dow Jones Newswires, 202-862-9294; [email protected]

Stock News for Novartis (NVS)
DateTimeHeadline
02/08/201706:00:00Propeller Health Enters into Collaboration to Connect Breezhaler™ D...
01/31/201714:59:00Trump Tells Pharmaceutical CEOs He Wants Prices Down -- Update
01/26/201703:02:00Novartis Weighs Alcon Spinoff -- WSJ
01/25/201705:28:00Vectura Group Says Bronchitis Inhaler Sales Trigger Milestone...
01/25/201703:42:00Novartis May Spin Off |Alcon Eye-Care Business
01/25/201701:51:00Novartis Announces Share Buyback as Dollar Hits Earnings
01/13/201716:21:00Supreme Court to Weigh How Soon Firms Can Sell Copycat Biotech...
01/06/201713:06:00Correction to Novartis to Pay Up to $1.6 Billion to Ionis
01/06/201706:17:00Novartis to Pay Up to $1.6 Billion to Ionis, Unit for Rights...
10/27/201616:40:00Amgen Sees Profit Increase, Raises Guidance
10/25/201604:40:00Novartis Profit Helped by GlaxoSmithKline Joint Venture
10/25/201603:53:00Novartis Profit Helped by GlaxoSmithKline Joint Venture -- Update
10/25/201602:01:00Novartis Net Income Rose in 3rd Quarter
10/21/201608:14:00Novartis AG 3Q 2016 - Forecast
10/05/201608:20:00Eli Lilly to Buy Boehringer Ingelheim Pet Vaccines Portfolio
10/02/201623:40:00Novo Nordisk Bets on Riskier Insulin Research
09/23/201613:11:00Novartis receives three new FDA approvals for the expanded use...
08/30/201618:50:00FDA Approves Novartis's Biosimilar to Amgen's Enbrel
08/30/201618:31:00FDA Approves Novartis's Biosimilar to Amgen's Enbrel
08/22/201608:50:00Eli Lilly, AstraZeneca Progress With Alzheimer's Drug

Novartis and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2016 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US